Effect of Hypoglycemic Drugs on Kisspeptin Expression in the Hypothalamic Arcuate Nucleus of PCOS Rats

• Published in: Diabetes, metabolic syndrome and obesity metabolic syndrome and obesity, 2023-09, Vol.16, p.2717-2732
• Main Authors: Zheng, Pingping, Lu, Yating, Tang, You, Xu, Fudong, Wang, Lin, Qian, Rui, Hui, Cancan, Xu, Qian, He, Jianle, Deng, Datong
• Format: Article
• Language: English
• Subjects: acarbose; Body weight; Brain; Dextrose; Glucose; Glycoproteins; Insulin; Insulin resistance; kisspeptin; Luteinizing hormone; Metformin; Original Research; pioglitazone; Pituitary hormones; polycystic ovary syndrome; pcos; Stein-Leventhal syndrome; Testosterone
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/DMSO.S421911

Background: To investigate the change in hypothalamic kisspeptin-1 (Kiss1) expression during the development of polycystic ovary syndrome (PCOS) and hypoglycemic drug intervention. Methods: Letrozole lavage was used to construct a polycystic ovary rat model. After successful modeling, we treated PCOS rats with metformin, pioglitazone, and acarbose, and we then observed changes in weight, estrus, glucose tolerance, insulin resistance, sex hormones, and hypothalamic kiss1 expression. Results: PCOS rats exhibited increased body weight, abnormal estrous cycle, impaired glucose tolerance, insulin resistance, increased testosterone level, increased luteinizing hormone level, and increased Kiss1 expression in the hypothalamus. However, intervention with metformin, pioglitazone, and acarbose improved the reproductive and metabolic disorders as well as reduced hypothalamic Kiss1 expression. Conclusion: The expression of hypothalamic Kiss1 may play an important role in the pathogenesis of PCOS. Metformin, pioglitazone, and acarbose may reduce the expression of hypothalamic Kiss1 by improving insulin resistance, thereby improving reproductive and metabolic disorders in PCOS rats. Keywords: polycystic ovary syndrome, PCOS, kisspeptin, metformin, pioglitazone, acarbose